Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Vladimir Kolenko

Center AffiliationsCancer Biology

Publications (41) (print view)

no pagination
Makhov P, Uzzo RG, Tulin AV, Kolenko VM. Histone-dependent PARP-1 inhibitors: A novel therapeutic modality for the treatment of prostate and renal cancers. Urol Oncol. 2020 May 08;.
Karpova Y, Wu C, Divan A, McDonnell ME, Hewlett E, Makhov P, Gordon J, Ye M, Reitz AB, Childers WE, Skorski T, Kolenko V, Tulin AV. Non-NAD-like PARP-1 inhibitors in prostate cancer treatment. Biochemical pharmacology. 2019 Sep;167:149-62.   PMCID: PMC6702078
Naito S, Ichiyanagi O, Ito H, Kabasawa T, Kanno H, Narisawa T, Fukuhara H, Yagi M, Kurota Y, Yamagishi A, Sakurai T, Nishida H, Kawazoe H, Yamanobe T, Kato T, Makhov P, Kolenko VM, Yamakawa M, Tsuchiya N. Expression of total and phospho 4EBP1 in metastatic and non-metastatic renal cell carcinoma. Oncol Lett. 2019 Apr;17(4):3910-8.   PMCID: PMC6403496
Zhao Z, Kurimchak A, Nikonova AS, Feiser F, Wasserman JS, Fowle H, Varughese T, Connors M, Johnson K, Makhov P, Lindskog C, Kolenko VM, Golemis EA, Duncan JS, Grana X. PPP2R2A prostate cancer haploinsufficiency is associated with worse prognosis and a high vulnerability to B55alpha/PP2A reconstitution that triggers centrosome destabilization. Oncogenesis. 2019 Dec 10;8(12):72.   PMCID: PMC6904742
Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo RG, Kolenko VM. Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies. Mol Cancer Ther. 2018 Jul;17(7):1355-64.   PMCID: PMC6034114
Makhov P, Naito S, Haifler M, Kutikov A, Boumber Y, Uzzo RG, Kolenko VM. The convergent roles of NF-kappaB and ER stress in sunitinib-mediated expression of pro-tumorigenic cytokines and refractory phenotype in renal cell carcinoma. Cell death & disease. 2018 Mar 07;9(3):374.   PMCID: PMC5841329
Makhov P, Naito S, Kolenko VM. Testing PARP Inhibitors Using a Murine Xenograft Model. Methods Mol Biol. 2017 Jan;1608:313-20.
Naito S, Makhov P, Astsaturov I, Golovine K, Tulin A, Kutikov A, Uzzo RG, Kolenko VM. LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma. Br J Cancer. 2017 Apr 25;116(9):1203-7.   PMCID: PMC5418451
Ji Y, Thomas C, Tulin N, Lodhi N, Boamah E, Kolenko V, Tulin AV. Charon Mediates Immune Deficiency-Driven PARP-1-Dependent Immune Responses in Drosophila. J Immunol. 2016 Aug 15;197(6):2382-9.   PMCID: PMC5010969
Thomas C, Ji Y, Lodhi N, Kotova E, Pinnola AD, Golovine K, Makhov P, Pechenkina K, Kolenko V, Tulin AV. Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo. EBioMedicine. 2016 Nov;13:90-8.   PMCID: PMC5264309
Golovine K, Makhov P, Naito S, Raiyani H, Tomaszewski J, Mehrazin R, Tulin A, Kutikov A, Uzzo RG, Kolenko VM. Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma. Cancer Biology & Therapy. 2015 May;16(5):743-9.   PMCID: 4623021
Ginzburg S, Golovine KV, Makhov PB, Uzzo RG, Kutikov A, Kolenko VM. Piperlongumine Inhibits NF-kappa B Activity and Attenuates Aggressive Growth Characteristics of Prostate Cancer Cells. The Prostate. 2014 Feb;74(2):177-86.   PMCID: PMC4052841
Kirsanov KI, Kotova E, Makhov P, Golovine K, Lesovaya EA, Kolenko VM, Yakubovskaya MG, Tulin AV. Minor grove binding ligands disrupt PARP-1 activation pathways. Oncotarget. 2014 Jan;5(2):428-37.   PMCID: PMC 3964218
Makhov P, Golovine K, Teper E, Kutikov A, Mehrazin R, Corcoran A, Tulin A, Uzzo RG, Kolenko VM. Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death. Br J Cancer. 2014 Feb 18;110(4):899-907.   PMCID: PMC3929888
Golovine KV, Makhov PB, Teper E, Kutikov A, Canter D, Uzzo RG, Kolenko VM. Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells. The Prostate. 2013 Jan;73(1):23-30.   PMCID: PMC3491117
Kolenko V, Teper E, Kutikov A, Uzzo R. Zinc and zinc transporters in prostate carcinogenesis. Nature Reviews Urology. 2013 Apr;10(4):219-26.   PMCID: PMC 3702371
Makhov PB, Golovine K, Kutikov A, Teper E, Canter DJ, Simhan J, Uzzo RG, Kolenko VM. Modulation of Akt/mTOR Signaling Overcomes Sunitinib Resistance in Renal and Prostate Cancer Cells. Molecular Cancer Therapeutics. 2012 Jul;11(7):1510-7.   PMCID: PMC 3491642
Makhov P, Golovine K, Canter D, Kutikov A, Simhan J, Corlew MM, Uzzo RG, Kolenko VM. Co-administration of piperine and docetaxel results in improved anti-tumor efficacy via inhibition of CYP3A4 activity. The Prostate. 2012 May;72(6):661-7.   PMCID: PMC3208085
Teper E, Makhov P, Golovine K, Canter DJ, Myers CB, Kutikov A, Sterious SN, Uzzo RG, Kolenko VM. The Effect of 5-Aminolevulinic Acid and Its Derivatives on Protoporphyrin IX Accumulation and Apoptotic Cell Death in Castrate-resistant Prostate Cancer Cells. Urology. 2012 Jan;80(6):1391e1-1391e7.   PMCID: PMC 3514607
Canter D, Kutikov A, Golovine K, Makhov P, Simhan J, Uzzo RG, Kolenko VM. Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines. The Canadian journal of urology. 2011 Aug;18(4):5819-25.   PMCID: PMC3182114
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

Vladimir Kolenko Sparkline Graph

Graph Interactions


Similar Investigators:

Keywords (MeSH):

Last updated on Saturday, July 04, 2020